RT Journal Article
SR Electronic
T1 Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.24.20153833
DO 10.1101/2020.07.24.20153833
A1 Díaz, Yayquier
A1 Ramos-Suzarte, Mayra
A1 Martín, Yordanis
A1 Calderón, Néstor Antonio
A1 Santiago, William
A1 Viñet, Orlando
A1 La, O Yulieski
A1 Pérez, Jorge
A1 Oyarzábal, Augusto
A1 Pérez, Yoan
A1 Lorenzo, Geidy
A1 Cepeda, Meylan
A1 Saavedra, Danay
A1 Mazorra, Zaima
A1 Estevez, Daymys
A1 Lorenzo-Luaces, Patricia
A1 Valenzuela, Carmen
A1 Caballero, Armando
A1 Leon, Kalet
A1 Crombet, Tania
A1 Hidalgo, Carlos Jorge
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.24.20153833.abstract
AB Introduction The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of Coronavirus Disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which nineteen elderly residents were positive for SARS-CoV-2.Methods Based on the increased susceptibility to viral-induced cytokine release syndrome inducing respiratory and systemic complications in this population, the patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody.Results All the patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable and 18 out of 19 (94.7%) patients were discharged clinically recovered with negative RT-PCR at 13 days (median). One dose of itolizumab, circulating IL-6 decreased in the first 24-48 hours in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminary assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control subjects were well-matched regarding age, comorbidities and severity of the disease. Every three moderately ill patients treated with itolizumab, one admission in intensive care unit (ICU) was prevented.Discussion/Conclusion Itolizumab was well tolerated. Its effect is associated with a reduction and controlling IL-6 serum levels. Moreover, treated patients had a favorable clinical outcome, considering their poor prognosis. This treatment is associated significantly with a decrease the risk to be admitted in ICU and reduced 10 times the risk of death. This study corroborates that the timely use of itolizumab, in combination with other antiviral and anticoagulant therapies, is associated with a reduction the COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19 and suggests its possible use in patients with cytokine release syndrome from other pathologies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRPCEC00000311 http://rpcec.sld.cu/trials/RPCEC00000311-EgClinical Protocols http://rpcec.sld.cu/trials/RPCEC00000311-Eg Funding StatementNo founding supported was received for this researchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical trial was approved by the ethics committee and by the Regulatory Agency for Medicines and Medical Equipment in Cuba (CECMED) on April 4, 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available